DNMT3A and acute myeloid leukemia: Since DNMT3A and TET2 mutations can prime HSCs to a pre-leukemic state through dysregulation of DNA methylation [51,52], it is proposed that assessing the aberrant DNA methylation pattern is valuable for an early detection of AML with no clinical manifestations.